Top 5 Stock Picks of Henrik Rhenman’s Rhenman Partners

2. Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Rhenman Partners’ Stake Value:  $35,333,000

Percentage of Rhenman Partners’ 13F Portfolio: 3.48%

Number of Hedge Fund Holders: 56

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), a biotechnology firm, is dedicated to the discovery, development, and commercialization of medicines that address the critical needs of people affected by rare, autoimmune, and severe inflammatory diseases. The company is divided into two divisions: Orphan and Inflammation. Its product portfolio includes 12 medicines for rare diseases, gout, ophthalmology, and inflammation. Rhenman Partners added Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) to its Q1 portfolio by buying 335,837 shares worth $35.33 million, representing 3.48% of the total holdings.

Here is what Carillon Tower Advisers has to say about Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) in their Q1 2021 investor letter:

“Horizon Therapeutics is a biopharmaceutical company whose primary focus is research, development, and marketing late-stage pharmaceutical products. After experiencing some unfortunate manufacturing hiccups in the later stages of 2020 for its key product, Tepezza, which is used in treating thyroid eye disease, the company recently received positive news that should relieve their supply issues going forward. With the manufacturing of Tepezza back online after being forced to halt due to Operation Warp Speed’s COVID-19 vaccine production orders, Horizon expects patient treatments to resume in mid-April.”